Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 141–150 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 141
- Medicine slug
- atropine
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 61
- Source count
- 16
- Agreement rate
- 0.6875
- Recorded readings
1%
- Numeric value
- 1
- Unit
- %
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b2d030e-c0ec-484b-a228-76011702cdd0 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f750135c-e6bf-4aa7-a343-87b1204df94f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The effect can last for up to 2 weeks in a normal eye. 12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:301ea0f4-a1dc-ad4f-e063-6294a90acc1c (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The effect can last for up to 2 weeks in a normal eye. 12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46e98d0b-3a04-7feb-e063-6394a90ac75e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4736dbc-b7c8-4b33-b7a8-a47c5654a127 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e30491ed-938e-4ef4-aa23-a2e94cbab0ed (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The effect can last for up to 2 weeks in a normal eye. 12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8718be5-8fa4-4c36-a4fd-fac7c3953f5a (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a116af5c-ba4c-408c-9a02-4bc33772aa8d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b39f5876-5d6f-4a8f-bd24-bd4be24ff568 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b5f78b2a-56d1-4400-9d2f-b033cc13d26e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The effect can last for up to 2 weeks in a normal eye. 12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution 1% was assessed in six healthy subjects, 24 to 29 years of age.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:127a7e32-a150-01d6-a66a-b7708d85809f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics The bioavailability of atropine sulfate ophthalmic solution, 1% was assessed in six healthy subjects, 24 to 29 years of age.
64 ± 29%
- Numeric value
- 64
- Unit
- %
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdb85b2-86d0-4f32-a8fa-272af48a191c (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In a study of healthy subjects, after topical ocular administration of 30 µL of atropine sulfate ophthalmic solution, 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20491566-e6eb-8d4a-3083-77ea429f7bc4 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In a study of healthy subjects, after topical ocular administration of 30 µL of atropine sulfate ophthalmic solution, 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeab333c-3cdb-45c0-9e22-949624d69fbc (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In a study of healthy subjects, after topical ocular administration of 30 μL of atropine sulfate ophthalmic solution 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8093125-ed1a-4eb6-9c81-52c5c7376481 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In a study of healthy subjects, after topical ocular administration of 30 μL of atropine sulfate ophthalmic solution, 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e294ce2b-6bb5-4f84-8a6d-ce2402ed926d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics In a study of healthy subjects, after topical ocular administration of 30 μL of atropine sulfate ophthalmic solution 1%, the mean (± SD) systemic bioavailability of l-hyoscyamine was reported to be approximately 64 ± 29% (range 19% to 95%) as compared to intravenous administration of atropine sulfate.
Projected row 142
- Medicine slug
- atropine
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 61
- Source count
- 16
- Agreement rate
- 0.6875
- Recorded readings
2 to 4 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 11
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 11 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9fd624a-9abd-dfea-e053-2a95a90a8e9d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38404931-980b-0019-e063-6394a90a933f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8663ff94-8bea-4061-9fd5-3ab2e85e862e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6acb3f07-9e32-4ad0-8336-e2f33d55b127 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:310c8a74-ea24-4357-8099-81e394b1634e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c15d3cc-7888-4c82-b3f8-a5d93c5523df (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532aa441-92ec-42d6-862a-639f8cfe9951 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84ba1689-3030-48d5-9cce-70b5a24a4033 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aab13de-04bf-2a14-e063-6294a90aae11 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2 to 4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423fc064-57cb-8308-e063-6394a90a2617 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine disappears from the blood following injection with a plasma half-life of about 2-4 hours.
2.5 ± 0.8 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 5
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 5 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bfdb85b2-86d0-4f32-a8fa-272af48a191c (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20491566-e6eb-8d4a-3083-77ea429f7bc4 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:aeab333c-3cdb-45c0-9e22-949624d69fbc (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8093125-ed1a-4eb6-9c81-52c5c7376481 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e294ce2b-6bb5-4f84-8a6d-ce2402ed926d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The mean (±SD) plasma half-life was reported to be approximately 2.5 ± 0.8 hours.
Projected row 143
- Medicine slug
- atropine
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 61
- Source count
- 42
- Agreement rate
- 0.97619
- Recorded readings
44%
- Numeric value
- 44
- Unit
- %
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9fd624a-9abd-dfea-e053-2a95a90a8e9d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80a31286-a741-4440-b200-290c08925d06 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 mcg/mL to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38404931-980b-0019-e063-6394a90a933f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8663ff94-8bea-4061-9fd5-3ab2e85e862e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fa81939-4495-28d5-e063-6394a90a1f2d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 µg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6acb3f07-9e32-4ad0-8336-e2f33d55b127 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d5c747f-3bf7-2597-e063-6394a90a828c (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad8916e7-206e-409e-2582-30d072845dd4 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2‑20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6fac578-c7bc-4b3c-a454-7889cc819118 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 µg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eeed115-0e17-c4b2-e063-6294a90a29b7 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b753894e-81f8-4e81-b07a-c338311ded5b (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:310c8a74-ea24-4357-8099-81e394b1634e (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f931937-7bc0-416b-e063-6294a90a28b5 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 µg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fbfdf718-befe-ad22-e053-6294a90a3715 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:739f384f-1a69-4953-93a0-aa6a76de0ecc (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0f5b0961-efe7-42c3-898e-2f7fc7fc90b1 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 mcg/mL to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:66710a22-2eaa-6dbd-e053-2a91aa0a900d (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d086f2-db9a-5e15-e063-6394a90abe18 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0060b971-19bd-2849-e063-6294a90afca8 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa1c953b-723b-1abe-e053-6394a90a967f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c15d3cc-7888-4c82-b3f8-a5d93c5523df (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:007728fc-f4cb-d519-e063-6394a90ae033 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532aa441-92ec-42d6-862a-639f8cfe9951 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:46ba6000-b842-449a-8dd4-7bb9dc7a74c5 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:768dc21a-b7d9-144c-e053-2991aa0af889 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84ba1689-3030-48d5-9cce-70b5a24a4033 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0aab13de-04bf-2a14-e063-6294a90aae11 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b72d0a82-6163-460f-965a-12f6da47370a (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ef1a1a0-93c1-e6b6-e063-6294a90aa2b6 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c434062a-cd44-e684-e053-2995a90a91c3 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4839e54-b350-4643-8e6e-f0437f5349d6 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a66eecf9-2d8b-4e2d-8a05-d718dcbc3542 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2-20 µg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:423fc064-57cb-8308-e063-6394a90a2617 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74106ef7-83bf-47ba-e053-2991aa0aaec1 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73de9878-a08a-4966-e053-2a91aa0ab0f6 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0d0ca2a-4267-41b7-e053-2a95a90a4726 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine’s plasma protein binding is about 44% and saturable in the 2–20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3eef6300-9c78-82b2-e063-6294a90a5499 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 µg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4a9559e8-7a34-4509-a8cc-ff0125694539 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2-20 μg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6fee1727-52b7-4f73-ab45-ef47d6a1c5bb (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 mcg/mL concentration range.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c82cb295-ffce-47d6-97ad-a8aa723f4e4f (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
Atropine's plasma protein binding is about 44% and saturable in the 2 to 20 μg/mL concentration range.
14 to 22%
- Numeric value
- 14
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2d4307d-da8f-49f5-aac0-02355dd9ffb7 (opens source in a new tab)
Atropine label
Version not recorded · Effective date not recorded
The protein binding of atropine is 14 to 22% in plasma.
Projected row 144
- Medicine slug
- auranofin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
26 days
- Numeric value
- Not parsed
- Unit
- Not recorded
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d688978b-8b91-4377-9f1d-89b805f5747c (opens source in a new tab)
Auranofin label
Version not recorded · Effective date not recorded
The mean terminal plasma half-life of auranofin gold at steady state was 26 days (range 21 to 31 days; n=5).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43ba3de1-ab2e-06f6-e054-00144ff8d46c (opens source in a new tab)
Auranofin label
Version not recorded · Effective date not recorded
The mean terminal plasma half-life of auranofin gold at steady state was 26 days (range 21 to 31 days; n=5).
Projected row 145
- Medicine slug
- axitinib
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
58%
- Numeric value
- 58
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84137882-e000-47da-bd5b-fa76ab3c76f9 (opens source in a new tab)
Axitinib label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of axitinib after an oral 5 mg dose is 58%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a903e31-936e-4ed7-8a59-59f32374f338 (opens source in a new tab)
Axitinib label
Version not recorded · Effective date not recorded
The mean absolute bioavailability of axitinib after an oral 5 mg dose is 58%.
Projected row 146
- Medicine slug
- axitinib
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
2.5 to 6.1 hours
- Numeric value
- 2.5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:84137882-e000-47da-bd5b-fa76ab3c76f9 (opens source in a new tab)
Axitinib label
Version not recorded · Effective date not recorded
Metabolism and Elimination The plasma half-life of INLYTA ranges from 2.5 to 6.1 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8a903e31-936e-4ed7-8a59-59f32374f338 (opens source in a new tab)
Axitinib label
Version not recorded · Effective date not recorded
Metabolism and Elimination The plasma half-life of INLYTA ranges from 2.5 to 6.1 hours.
Projected row 147
- Medicine slug
- azacitidine
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 26
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
11%
- Numeric value
- 11
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e95e33f-8aba-4f19-b332-2416580d358b (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Absorption The mean oral bioavailability is approximately 11% relative to subcutaneous administration.
89%
- Numeric value
- 89
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38a1247-28c8-a911-e691-a983a2f9a6e3 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
The bioavailability of SC Azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve.
Projected row 148
- Medicine slug
- azacitidine
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 26
- Source count
- 2
- Agreement rate
- 0.5
- Recorded readings
0.5 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Absorption Azacitidine is rapidly absorbed after subcutaneous administration with a median time to C max (T max ) of 0.5 hour.
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e95e33f-8aba-4f19-b332-2416580d358b (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
The median time to peak plasma concentration of azacitidine is 1 hour.
Projected row 149
- Medicine slug
- azacitidine
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 26
- Source count
- 26
- Agreement rate
- 0.961538
- Recorded readings
76 ± 26 L
- Numeric value
- 76
- Unit
- L
- Source records
- 25
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 25 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d15b3ec-ed08-48c6-a400-34e55974afad (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f89fcbd-d3f4-4112-8733-69baea41255e (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff73515d-bd55-4eb5-992b-d2138c80887e (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33397835-15a9-d89f-bd75-8b915f5c4dbf (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d24f1fc5-17c6-4e0c-b852-72692e835cff (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3bc4f406-2ec7-7169-e063-6394a90a81d9 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Distribution Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b96b508-046b-49ae-aefe-6d39c89a1d0e (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:80a43736-0598-4e4b-85ba-e29daa290c8f (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:060d56e7-1a24-87c1-7f40-149ecf424f7c (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5804d999-96eb-4fd1-b7d8-de7867c5f1d6 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cd9db533-8a49-4d01-99e2-b2db8db1ed38 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f9f1563-f8b2-4e83-a4ec-af41fed0e627 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9abb489d-ce54-4140-83f6-b756f00b0967 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d38a1247-28c8-a911-e691-a983a2f9a6e3 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following IV dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71d8d758-86c9-b571-aed1-719654fd4b82 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c0a2d5f-8c34-4c04-8425-7543965cedd4 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3495a71a-cc04-4776-851f-f185956f32af (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:97b0917a-03fa-4cc4-91cf-1bed57a988c9 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70140e11-33f1-2240-e053-2991aa0a0480 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6a5ca37-37e8-ab65-bc0b-9c0682ab52f7 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:81366ec1-9689-4857-ded6-3d6342fe5132 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f02c9bef-e47f-4b70-95f6-9341d87346ed (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3b594aba-e798-4105-b801-0b0d970747c1 (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ecd108bd-bb5f-4b2e-ad91-210fca452e9b (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Mean volume of distribution following intravenous dosing is 76 ± 26 L.
881 L
- Numeric value
- 881
- Unit
- L
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e95e33f-8aba-4f19-b332-2416580d358b (opens source in a new tab)
Azacitidine label
Version not recorded · Effective date not recorded
Distribution The mean (CV%) apparent volume of distribution (V z /F) of azacitidine is 881 L (67%).
Projected row 150
- Medicine slug
- azathioprine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2f994aed-f8e7-4967-a167-b22b783b4192 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2b9f91b9-7959-65e7-e063-6294a90a3680 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f3219f-898f-4d05-a430-c2b3f5255af1 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5116b22b-1460-5535-e063-6394a90acbe5 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9050af7a-19c6-4670-937a-9445605de995 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9ffe79a1-ac91-4a7b-a9e3-7c84bfa9ddf0 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d4c7d621-9642-4027-e053-2995a90a9220 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc6dc4bd-2121-4613-9d90-4a504010c98a (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8429e025-b79d-dae7-e053-2a91aa0a7fe5 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f93d9408-7b3f-b423-e053-6294a90a31ec (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d72ede2c-1a9b-4717-80a7-b76a6a499936 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:606101a0-6244-7eff-e053-2a91aa0acadd (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d288e484-32fc-4b46-b504-d75a0fac8663 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ffa2fce-895d-469e-8667-b078560aec5f (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ceab8e8b-d022-4d0c-a552-cc5782446248 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c49b7cc5-0eed-43b7-b7ad-cbb1b6f0cd2c (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f251f372-c881-483e-8035-c6a8a6bfb4e8 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1b0fa3e-11c3-46d0-9537-6b372c2a1b56 (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:040d010a-b1b2-4db7-905d-8aa7f1bab0cd (opens source in a new tab)
Azathioprine label
Version not recorded · Effective date not recorded
Maximum serum radioactivity occurs at 1 to 2 hours after oral 35 S-azathioprine and decays with a half-life of 5 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=140Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.